ISM1354 (GIPR antagonist)
Insilico Medicine: company profile
Preclinical candidate per company
Since , the date of the source that reports this phase.
Summary
ISM1354 is a GIPR antagonist from Insilico Medicine. The source describes it as small molecule. It is being developed for obesity. Per the company, it was at Preclinical candidate as of Sep 30, 2026. The AI role named in the source is molecule design. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. The latest dated source is from Oct 1, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine
- Indication
- Obesity
- Therapeutic area
- Metabolic
- Modality
- Small molecule
- AI role
- Molecule design
- Phase in the source
- Preclinical candidate, as of Sep 30, 2026
- Phase source
- X only
- Board column
- Preclinical
- Trial record
- none (preclinical)
AI evidence
AI source: Company
“the nomination of ISM1354, an AI-driven novel small molecule preclinical candidate (PCC) targeting GIPR”
Milestone timeline
-
Official X post: Preclinical candidate
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.